Skip to main content
Clinical Trials/NCT02379182
NCT02379182
Completed
N/A

Randomized Controlled Trial To Evaluate The Effect Of Vitalstim In Patients With Chronic Post-stroke Oropharyngeal Dysphagia

Pere Clave1 site in 1 country90 target enrollmentOctober 2014

Overview

Phase
N/A
Intervention
Not specified
Conditions
Deglutition Disorders
Sponsor
Pere Clave
Enrollment
90
Locations
1
Primary Endpoint
Change in Penetration-Aspiration scores
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Prospective, randomized, controlled, three-arm, open-label, blinded analysis. Patients admitted with stroke diagnosis and with suspected dysphagia that meet the initial inclusion and exclusion criteria will be consented into the clinical investigation. Patients who meet the second set of inclusion criteria (dysphagia confirmed by VFS) will be randomized to either active (motor or sensory) or standard treatment (control group) arms.

Subjects included in this clinical investigation will be evaluated at screening, 1-week, 3-months and at 12-months post treatment.

The main aim of the study will be to assess the effect of VitalStim therapy on improving the safety of swallow according to the VFS, after the treatment and at 1-year follow up, on patients with chronic post-stroke OD.

Registry
clinicaltrials.gov
Start Date
October 2014
End Date
July 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Pere Clave
Responsible Party
Sponsor Investigator
Principal Investigator

Pere Clave

MD, PhD

Hospital de Mataró

Eligibility Criteria

Inclusion Criteria

  • Subject is over 18 years of age.
  • Subject is suspected of having oropharyngeal dysphagia.
  • Subject is able to comply with videofluoroscopy protocol.
  • Subject diagnosed with stroke.
  • Subject has no previous history of dysphagia.
  • Subjects who are able to give voluntary, written informed consent to participate in the clinical investigation and from whom consent has been obtained/ or a consultee has consented on the subjects behalf in line with nationally agreed guidelines concerning adults unable to consent for themselves.
  • Subject is not currently participating in any other interventional clinical study.
  • Subject is able to comply with the protocol requirements
  • Subject scores 0 or 1 on question 1a of NIHSS
  • Randomization Inclusion Criteria:

Exclusion Criteria

  • Subject stroke event occurred less than 3 months ago.
  • Subject is pregnant or a nursing mother.
  • Subject, in the opinion of the investigator, has advanced dementia
  • Subject fitted with a pacemaker or implantable cardiac defibrillator
  • Subject is dysphagic from conditions other than stroke
  • Subject has been diagnosed with a progressive neurological disorder, such as Parkinson's disease or Multiple Sclerosis.
  • Subject with active neoplasm or infection process.

Outcomes

Primary Outcomes

Change in Penetration-Aspiration scores

Time Frame: baseline and 1 year

Secondary Outcomes

  • Incidence of all adverse events(1 year)
  • Time from randomisation to death(1 year)
  • Change in pharyngeal residue prevalence(1 year)
  • Frequency of chest infections(1 year)
  • Change in EAT-10 scores(1 year)

Study Sites (1)

Loading locations...

Similar Trials